SOD and GSH-Px activities were elevated in the MET and BHRS treatment groups compared to those in the T2DM group, whereas MDA levels were decreased in the MET and BHRS treatment groups compared to those in the T2DM group (Table 1). The gene discussed is SOD1; the disease is type 2 diabetes mellitus.